Pharmaceutical Pfizer acknowledged this Friday (17) that its double-dose vaccine against Covid-19 has not been shown to be effective in studies with children aged 2 to 5 years and informed who will now try to add a third application after two months to increase this effectiveness.
If the study shows greater effectiveness with this third injection, Pfizer will present the formulation to regulatory agencies in the first half of 2022 for approval of an emergency use permit.
Studies in children have shown, however, that the double dose was adequate for infants 6 to 24 months of age. In addition, the company says it will consider whether to recommend a third dose of 10 micrograms for people aged between 5 and 12 years.
#Pfizer #doubledose #Covid #vaccine #effective #children #years
